7-May-2025 6:05 AM CST - Business Wire Ironwood Pharmaceuticals Reports First Quarter 2025 Results Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its first quarter 2025 results and recent business performance. LINZESS demand continues to be strong, and we remain on track to meet our full-year 2025 guidance and further, recently raised our adjusted EBITDA guidance. We are making a concerted effort to maximize st
30-Apr-2025 3:25 PM CST - Business Wire Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, May 7th at 12:00 p.m. ET at the New York Hilton Midtown. A live webcast of Ironwoods fireside chat will be accessible through the Investors section of the companys website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwoods website following the conference. About Ironwood
27-Feb-2025 6:00 AM CST - Business Wire Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its fourth quarter and full year 2024 results and recent business performance. We believe that 2025 marks the beginning of a transformation for Ironwood that will lay the foundation for growth, long-term value creation, and the delivery of new medicines to rare diseas
20-Feb-2025 3:00 PM CST - Business Wire Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its fourth quarter and full year 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, February 27, 2025. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international) using conference ID number and event passcode 2530602. To access the webcast, please visit the Investors section of Ironwoods w
29-Jan-2025 3:05 PM CST - Business Wire Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced a streamlined strategic focus on advancing and realizing the potential of apraglutide for the treatment of short bowel syndrome (SBS) patients who are dependent on parenteral support. In line with this strategic update, Ironwood will be reducing its workforce by app
26-Nov-2024 3:01 PM CST - Business Wire Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024 at 12:30 p.m. ET at the Lotte New York Palace. A live webcast of Ironwoods fireside chat will be accessible through the Investors section of the companys website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwoods website following the confe
13-Nov-2024 3:01 PM CST - Business Wire Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Operating Officer and Chief Financial Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 7:30 a.m. GT at the Waldorf Hilton in London. A live webcast of Ironwoods fireside chat will be accessible through the Investors section of the companys website at www.ironwoodpharma.com. A replay of the webcast will be a
7-Nov-2024 6:00 AM CST - Business Wire Ironwood Pharmaceuticals Reports Third Quarter 2024 Results Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today reported its third quarter 2024 results and recent business performance. LINZESS continued to deliver robust prescription demand growth in the third quarter, said Tom McCourt, chief executive officer of Ironwood Pharmaceuticals. LINZESS extended units and new-to-brand prescriptions each increased 13% year-over-year, respectively, reinforcing that patients and health care professiona
24-Oct-2024 3:00 PM CST - Business Wire Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its third quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, November 7, 2024. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international) using conference ID number and event passcode 2530602. To access the webcast, please visit the Investors section of Ironwoods website at www.ir
7-May-2025 6:05 AM CST - Business Wire Ironwood Pharmaceuticals Reports First Quarter 2025 Results Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its first quarter 2025 results and recent business performance. LINZESS demand continues to be strong, and we remain on track to meet our full-year 2025 guidance and further, recently raised our adjusted EBITDA guidance. We are making a concerted effort to maximize st
30-Apr-2025 3:25 PM CST - Business Wire Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, May 7th at 12:00 p.m. ET at the New York Hilton Midtown. A live webcast of Ironwoods fireside chat will be accessible through the Investors section of the companys website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwoods website following the conference. About Ironwood
27-Feb-2025 6:00 AM CST - Business Wire Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its fourth quarter and full year 2024 results and recent business performance. We believe that 2025 marks the beginning of a transformation for Ironwood that will lay the foundation for growth, long-term value creation, and the delivery of new medicines to rare diseas
20-Feb-2025 3:00 PM CST - Business Wire Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its fourth quarter and full year 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, February 27, 2025. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international) using conference ID number and event passcode 2530602. To access the webcast, please visit the Investors section of Ironwoods w
29-Jan-2025 3:05 PM CST - Business Wire Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced a streamlined strategic focus on advancing and realizing the potential of apraglutide for the treatment of short bowel syndrome (SBS) patients who are dependent on parenteral support. In line with this strategic update, Ironwood will be reducing its workforce by app
26-Nov-2024 3:01 PM CST - Business Wire Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024 at 12:30 p.m. ET at the Lotte New York Palace. A live webcast of Ironwoods fireside chat will be accessible through the Investors section of the companys website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwoods website following the confe
13-Nov-2024 3:01 PM CST - Business Wire Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Operating Officer and Chief Financial Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 7:30 a.m. GT at the Waldorf Hilton in London. A live webcast of Ironwoods fireside chat will be accessible through the Investors section of the companys website at www.ironwoodpharma.com. A replay of the webcast will be a
7-Nov-2024 6:00 AM CST - Business Wire Ironwood Pharmaceuticals Reports Third Quarter 2024 Results Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today reported its third quarter 2024 results and recent business performance. LINZESS continued to deliver robust prescription demand growth in the third quarter, said Tom McCourt, chief executive officer of Ironwood Pharmaceuticals. LINZESS extended units and new-to-brand prescriptions each increased 13% year-over-year, respectively, reinforcing that patients and health care professiona
24-Oct-2024 3:00 PM CST - Business Wire Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its third quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, November 7, 2024. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international) using conference ID number and event passcode 2530602. To access the webcast, please visit the Investors section of Ironwoods website at www.ir
